Chemokines in thyroid autoimmunity

Best Pract Res Clin Endocrinol Metab. 2023 Mar;37(2):101773. doi: 10.1016/j.beem.2023.101773. Epub 2023 Mar 9.

Abstract

The chemokine receptor CXCR3 and its chemokines CXCL9, CXCL10, and CXCL11 are involved in the pathogenesis of autoimmune diseases. Th1 lymphocytes are recruited by Th1 chemokines, secreted by damaged cells. In inflamed tissues, the attracted Th1 lymphocytes induce the IFN-gamma and TNF-alpha release, that stimulates the secretion of Th1 chemokines, initiating and reiterating an amplification feedback loop. Autoimmune thyroid disorders (AITD) are the most recurrent autoimmune diseases, including Graves' disease (GD) and autoimmune thyroiditis, clinically defined by thyrotoxicosis and hypothyroidism, respectively. Graves' ophthalmopathy is one of GD extrathyroidal manifestations, occurring in ~30-50% of GD patients. In the early phase of AITD, the Th1 immune response is prevalent, and a following switch to a Th2 immune response has been shown in the late, inactive, phase. The reviewed data underline the importance of chemokines in thyroid autoimmunity and suggest CXCR3-receptor and its chemokines as potential targets of novel drugs for these disorders.

Keywords: Autoimmune thyroid disorders; Autoimmune thyroiditis; CCL2; CXCL10; CXCL11; CXCL9; CXCR3; Chemokines; Cytokines; Graves’ disease; Graves’ ophthalmopathy.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases*
  • Autoimmunity
  • Chemokine CXCL10
  • Graves Disease*
  • Graves Ophthalmopathy*
  • Hashimoto Disease*
  • Humans

Substances

  • Chemokine CXCL10